MedPath

LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive

Phase 4
Completed
Conditions
Acute Lymphoblastic Leukemia
Registration Number
NCT00526305
Lead Sponsor
PETHEMA Foundation
Brief Summary

Due to ALL Ph+ patients should receive a different treatment, is proposed a therapeutical protocol with: intensification treatment of induction to increment the CR rate, allogenic transplantation in first CR, autologous transplantation follow by alfa interferon in patients cannot done allogenic transplantation.

Detailed Description

Remission Induction:

* Vincristine (VCR): 1,5 mg/m2 i.v., days 1 and 8

* Daunorubicin (DNR): 60 mg/m2 i.v., days 1 and 8.

* Prednisone (PDN): 60 mg/m2/day, i.v. or p.o., days 1 to 14

* L-asparaginase (L-ASA): 10.000 UI/m2, i.v.days 5-7 and 11-13

Results:

1. Standard response: The induction treatment will be completed with the same drugs, changing L-ASA to ARA-C, during two more weeks

2 Slow response. Chemotherapy with mitoxantrone and high dose ARA-C

Intrathecal chemotherapy:

Treatment with mitoxantrone, ARA-C e hydrocortisone, days 1 and 22

CONSOLIDATION TREATMENT 1

Start in two weeks after last dose of induction chemotherapy:

* Mercaptopurine (MP) 50 mg/m2, p.o., days 1-7, 28-35 and 56-63

* Mitoxantrone (MTX): 3g/m2, i.v., in 24 hours, day 1, 28 and 56.

* VM-26: 150 mg/m2 every 12 horas, i.v. (infusión 1 hora), días 14 y 42

* ARA-C: 500 mg/m2 cada 12 hours, i.v., in 3 hours, days 14-15 and 42-43

* Intrathecal treatment, days 28 and 56.

6.4. CONSOLIDATION TREATMENT 2

Start in a week after last dose of mercaptopurine of previous cycle

* Dexamethasone (DXM):

* 10 mg/m2 day, p.o. or i.v. days 1-14

* 5 mg/m2 day, p.o. or i.v., days 15-21

* Vincristine (VCR): 1,5 mg/m2 i.v., days 1 and 8 and 15

* Daunorubicin (DNR): 30 mg/m2 i.v., days 1, 2, 8 and 9.

* CFM 600 mg/m2 day, i.v., days 1 and 15

* L-asparaginase (L-ASA): 10.000 UI/m2, i.v.or im , days 1-3 and 15-17

* Intrathecal treatment days 1 and 15.

TRANSPLANTATION

Hematopoietic autologous transplantation with related donor, one or two months after last dose of consolidation treatment.

Hematopoietic autologous transplantation with unrelated donor, in patients younger than 45, and with PS 0-1

Hematopoietic autologous transplantation in patients without related donor and without unrelated donor after six months searching

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria

ALL BCR/ABL+ patients Age < 65 years No previous treatment

Exclusion Criteria
  1. Other LLA variability
  2. Previous history of coronary valvular, hypertensive cardiopathy illness
  3. Chronic hepatic illness
  4. Chronic respiratory insufficiency
  5. Renal insufficiency not caused by LLA
  6. Severe neurological problems not caused by LLA
  7. Severe affection of the performance status (grade 3-4 OMS gradation) not caused by LLA

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
To evaluate the efficacy of treatment in order to response rate, relapse free survival and overall survival5 years
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (49)

Hospital General de Segovia

🇪🇸

Segovia, Spain

Hospital Universitario de Canarias

🇪🇸

Tenerife, Spain

H.U. Virgen del Rocio

🇪🇸

Sevilla, Spain

Hospital Clínico Universitario de Valencia

🇪🇸

Valencia, Spain

Hospital dr. Peset

🇪🇸

Valencia, Spain

Hospital La Fe

🇪🇸

Valencia, Spain

Complejo Hospitalario de Pontevedra_Hospital Montecelo

🇪🇸

Pontevedra, Spain

Complejo Hospitalario Universitario de Vigo

🇪🇸

Vigo, Spain

Hospital de Galdakao

🇪🇸

Vizcaya, Spain

Complexo Hospitalario Xeral-Calde

🇪🇸

Lugo, Spain

Hospital Clínico de Valladolid

🇪🇸

Valladolid, Spain

Hospital Clínico Lozano Blesa

🇪🇸

Zaragoza, Spain

Hospital Central de Asturias

🇪🇸

Oviedo, Asturias, Spain

Hospital de Navarra

🇪🇸

Pamplona, Navarra, Spain

Hospital Verge de la Cinta

🇪🇸

Tortosa, Tarragona, Spain

Complejo Hospitalario Universitario de Albacete

🇪🇸

Albacete, Spain

Hospital Clínic

🇪🇸

Valencia, Spain

Hospital General de Alicante

🇪🇸

Alicante, Spain

Hospital Ntra. Sra. Sonsoles

🇪🇸

Avila, Spain

Hospital de Badalona Germans Trias i Pujol

🇪🇸

Badalona, Spain

Hospital del Mar

🇪🇸

Barcelona, Spain

Complejo Hospitalario León

🇪🇸

Leon, Spain

Hospital de Jerez de la Frontera

🇪🇸

Jerez de La Frontera, Spain

Hospital 12 de Octubre

🇪🇸

Madrid, Spain

Basurtuko Ospitalea

🇪🇸

Basurto, Spain

Hospital Arnau de Vilanova

🇪🇸

Lleida, Spain

Clínica Puerta de Hierro

🇪🇸

Madrid, Spain

Hospital Clínico San Carlos de Madrid

🇪🇸

Madrid, Spain

Hospital de la Princesa

🇪🇸

Madrid, Spain

Hospital Universitario de la Princesa

🇪🇸

Madrid, Spain

Althaia, Xarxa Asistencial de Manresa

🇪🇸

Manresa, Spain

Hospital General Universitario Gregorio Marañón, Madrid

🇪🇸

Madrid, Spain

Hospital General Morales Meseguer

🇪🇸

Murcia, Spain

Complejo Asistencial Son Dureta

🇪🇸

Palma de Mallorca, Spain

Hospital Santa María del Rosell

🇪🇸

Murcia, Spain

Hospital General Universitario Morales Meseguer.

🇪🇸

Murcia, Spain

Hospital Son Llatzer

🇪🇸

Palma de Mallorca, Spain

Corporació Sanitaria Parc Taulí

🇪🇸

Sabadell, Spain

Hospital Clínico Universitario de Salamanca

🇪🇸

Salamanca, Spain

Hospital de Cruces

🇪🇸

Bilbao, Spain

Complejo Hospitalario Universitario de Santiago

🇪🇸

Santiago de Compostela, Spain

H. Carlos Haya

🇪🇸

Málaga, Spain

Hospital vall d'Hebrón

🇪🇸

Barcelona, Spain

Hospital de Sagunto

🇪🇸

Sagunto, Spain

Hospital de Sant Pau

🇪🇸

Barcelona, Spain

. Hospital Clínico Universitario Virgen de la Victoria

🇪🇸

Málaga, Spain

Hospital General Universitario

🇪🇸

Valencia, Spain

Clínica Universitaria de Navarra

🇪🇸

Pamplona, Spain

Hospital general de Castellón

🇪🇸

Castello, Castellón, Spain

© Copyright 2025. All Rights Reserved by MedPath